IgG1-κ biclonal gammopathy associated with multiple myeloma suggests a regulatory mechanism

M. Pizzolato, G. Bragantini, P. Bresciani, S. Pavlovsky, J. Chuba, Ruben Vidal, A. Rostagno, J. Ghiso

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Multiclonal gammopathies associated with multiple myeloma may result either from a neoplastic transformation of a cell clone undergoing immunoglobulin class switching or from independent transforming events yielding proliferation of unrelated plasma cell clones. The simultaneous presence of more than one neoplastic clone may possess regulatory implications in terms of cell proliferation, clonal expansion, secretion of M-components or response to chemotherapy. We report a patient, diagnosed with multiple myeloma stage IIIa, who presented with two well-defined homogenous IgG1-κ components in the serum (designated WER-1 and WER-2) with striking differences in their plasma concentration and response to the classic melphalan/prednisone treatment. Immunochemical characterization and amino terminal sequence analysis of both the heavy and light chains of each M- component undoubtedly determined their biclonal origin. WER-1 was identified as IgG1(VHII)-κI while WER-2 was classified as IgG1(VHIII)-κIII. The plateau phase was characterized by very low or undetectable levels of WER-2, a high, almost constant, concentration of WER-1 and the absence of Bence Jones proteinuria, whereas these parameters were completely reversed during the escape phase with levels resembling those observed at the time of diagnosis. The statistically significant negative correlation between the biclonal components and the different susceptibility to the treatment clearly suggests regulatory interactions between the clones WER-1 and WER-2.

Original languageEnglish (US)
Pages (from-to)503-508
Number of pages6
JournalBritish Journal of Haematology
Volume102
Issue number2
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Multiple Myeloma
Clone Cells
Immunoglobulin G
Myeloma Proteins
Neoplastic Cell Transformation
Immunoglobulin Class Switching
Melphalan
Prednisone
Plasma Cells
Proteinuria
Sequence Analysis
Cell Proliferation
Light
Drug Therapy
Therapeutics
Serum

Keywords

  • Biclonal gammopathy
  • Clonal regulation
  • Melphalan
  • Myeloma
  • Prednisone

ASJC Scopus subject areas

  • Hematology

Cite this

IgG1-κ biclonal gammopathy associated with multiple myeloma suggests a regulatory mechanism. / Pizzolato, M.; Bragantini, G.; Bresciani, P.; Pavlovsky, S.; Chuba, J.; Vidal, Ruben; Rostagno, A.; Ghiso, J.

In: British Journal of Haematology, Vol. 102, No. 2, 1998, p. 503-508.

Research output: Contribution to journalArticle

Pizzolato, M, Bragantini, G, Bresciani, P, Pavlovsky, S, Chuba, J, Vidal, R, Rostagno, A & Ghiso, J 1998, 'IgG1-κ biclonal gammopathy associated with multiple myeloma suggests a regulatory mechanism', British Journal of Haematology, vol. 102, no. 2, pp. 503-508. https://doi.org/10.1046/j.1365-2141.1998.00805.x
Pizzolato, M. ; Bragantini, G. ; Bresciani, P. ; Pavlovsky, S. ; Chuba, J. ; Vidal, Ruben ; Rostagno, A. ; Ghiso, J. / IgG1-κ biclonal gammopathy associated with multiple myeloma suggests a regulatory mechanism. In: British Journal of Haematology. 1998 ; Vol. 102, No. 2. pp. 503-508.
@article{b968d1a4606c4a0f90920c056138c502,
title = "IgG1-κ biclonal gammopathy associated with multiple myeloma suggests a regulatory mechanism",
abstract = "Multiclonal gammopathies associated with multiple myeloma may result either from a neoplastic transformation of a cell clone undergoing immunoglobulin class switching or from independent transforming events yielding proliferation of unrelated plasma cell clones. The simultaneous presence of more than one neoplastic clone may possess regulatory implications in terms of cell proliferation, clonal expansion, secretion of M-components or response to chemotherapy. We report a patient, diagnosed with multiple myeloma stage IIIa, who presented with two well-defined homogenous IgG1-κ components in the serum (designated WER-1 and WER-2) with striking differences in their plasma concentration and response to the classic melphalan/prednisone treatment. Immunochemical characterization and amino terminal sequence analysis of both the heavy and light chains of each M- component undoubtedly determined their biclonal origin. WER-1 was identified as IgG1(VHII)-κI while WER-2 was classified as IgG1(VHIII)-κIII. The plateau phase was characterized by very low or undetectable levels of WER-2, a high, almost constant, concentration of WER-1 and the absence of Bence Jones proteinuria, whereas these parameters were completely reversed during the escape phase with levels resembling those observed at the time of diagnosis. The statistically significant negative correlation between the biclonal components and the different susceptibility to the treatment clearly suggests regulatory interactions between the clones WER-1 and WER-2.",
keywords = "Biclonal gammopathy, Clonal regulation, Melphalan, Myeloma, Prednisone",
author = "M. Pizzolato and G. Bragantini and P. Bresciani and S. Pavlovsky and J. Chuba and Ruben Vidal and A. Rostagno and J. Ghiso",
year = "1998",
doi = "10.1046/j.1365-2141.1998.00805.x",
language = "English (US)",
volume = "102",
pages = "503--508",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - IgG1-κ biclonal gammopathy associated with multiple myeloma suggests a regulatory mechanism

AU - Pizzolato, M.

AU - Bragantini, G.

AU - Bresciani, P.

AU - Pavlovsky, S.

AU - Chuba, J.

AU - Vidal, Ruben

AU - Rostagno, A.

AU - Ghiso, J.

PY - 1998

Y1 - 1998

N2 - Multiclonal gammopathies associated with multiple myeloma may result either from a neoplastic transformation of a cell clone undergoing immunoglobulin class switching or from independent transforming events yielding proliferation of unrelated plasma cell clones. The simultaneous presence of more than one neoplastic clone may possess regulatory implications in terms of cell proliferation, clonal expansion, secretion of M-components or response to chemotherapy. We report a patient, diagnosed with multiple myeloma stage IIIa, who presented with two well-defined homogenous IgG1-κ components in the serum (designated WER-1 and WER-2) with striking differences in their plasma concentration and response to the classic melphalan/prednisone treatment. Immunochemical characterization and amino terminal sequence analysis of both the heavy and light chains of each M- component undoubtedly determined their biclonal origin. WER-1 was identified as IgG1(VHII)-κI while WER-2 was classified as IgG1(VHIII)-κIII. The plateau phase was characterized by very low or undetectable levels of WER-2, a high, almost constant, concentration of WER-1 and the absence of Bence Jones proteinuria, whereas these parameters were completely reversed during the escape phase with levels resembling those observed at the time of diagnosis. The statistically significant negative correlation between the biclonal components and the different susceptibility to the treatment clearly suggests regulatory interactions between the clones WER-1 and WER-2.

AB - Multiclonal gammopathies associated with multiple myeloma may result either from a neoplastic transformation of a cell clone undergoing immunoglobulin class switching or from independent transforming events yielding proliferation of unrelated plasma cell clones. The simultaneous presence of more than one neoplastic clone may possess regulatory implications in terms of cell proliferation, clonal expansion, secretion of M-components or response to chemotherapy. We report a patient, diagnosed with multiple myeloma stage IIIa, who presented with two well-defined homogenous IgG1-κ components in the serum (designated WER-1 and WER-2) with striking differences in their plasma concentration and response to the classic melphalan/prednisone treatment. Immunochemical characterization and amino terminal sequence analysis of both the heavy and light chains of each M- component undoubtedly determined their biclonal origin. WER-1 was identified as IgG1(VHII)-κI while WER-2 was classified as IgG1(VHIII)-κIII. The plateau phase was characterized by very low or undetectable levels of WER-2, a high, almost constant, concentration of WER-1 and the absence of Bence Jones proteinuria, whereas these parameters were completely reversed during the escape phase with levels resembling those observed at the time of diagnosis. The statistically significant negative correlation between the biclonal components and the different susceptibility to the treatment clearly suggests regulatory interactions between the clones WER-1 and WER-2.

KW - Biclonal gammopathy

KW - Clonal regulation

KW - Melphalan

KW - Myeloma

KW - Prednisone

UR - http://www.scopus.com/inward/record.url?scp=0031871163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031871163&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.1998.00805.x

DO - 10.1046/j.1365-2141.1998.00805.x

M3 - Article

C2 - 9695965

AN - SCOPUS:0031871163

VL - 102

SP - 503

EP - 508

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -